<DOC>
	<DOCNO>NCT01094600</DOCNO>
	<brief_summary>The aim study evaluate S-MRCP , comparison direct pancreatic function , measure pancreatic exocrine function patient symptoms suspicious insufficiency . We hypothesize S-MRCP imaging parameter correlate well direct pancreatic exocrine functioning .</brief_summary>
	<brief_title>Comparison Secretin-enhanced Magnetic Resonance Cholangiopancreatography ( S-MRCP ) Endoscopic Pancreatic Function Test ( ePFT ) Diagnosing Pancreatic Exocrine Insufficiency</brief_title>
	<detailed_description>Surgical resection offer hope cure pancreatic adenocarcinoma . While perioperative mortality rate decline recent year , pancreatic resection still associate significant postoperative malnutrition , maldigestion , glucose intolerance , mostly result pancreatic insufficiency . Quantifying individual pancreatic function remain challenge , essential improve survival quality life pancreatic cancer patient . Secretin-enhanced magnetic resonance cholangiopancreatography ( S-MRCP ) recently emerge widely-accepted noninvasive technique assess morphological change pancreatic duct , well functional secretory capacity gland . The aim study evaluate S-MRCP mean evaluate pancreatic exocrine insufficiency . This prospective study twelve patient undergone pancreatic resection symptom abdominal pain , steatorrhea weight loss . We compare quantitative parameter S-MRCP ( maximal change pancreatic duct diameter volume secretin administration ) endoscopic pancreatic function test ( maximal bicarbonate concentration duodenal aspirate secretin administration ) .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Secretin</mesh_term>
	<criteria>18 year age old Tissueconfirmed diagnosis pancreatic adenocarcinoma Undergone surgical resection adenocarcinoma le 3 month prior enrollment Report significant abdominal pain/bloating steatorrhea &gt; 3x/week demonstrate weight loss correspond &gt; 10 % presurgery BMI . Scheduled EGD/EUS investigate clinical indicator . History radiation therapy abdomen prior surgery Any contraindication MRI , include limited implanted metal device ( e.g . pacemaker , berry aneurysm clip , neural stimulator , cochlear implant , metal eye ) Presence pancreatic duct stent Treatment investigational drug within 1 month prior day study drug administration Current enrollment interventional study Creatinine great 2.0 Significant liver disease , liver mass , evidence portal hypertension Pregnancy History sensitivity secretin Unwilling unable sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Pancreatic resection</keyword>
	<keyword>Synthetic human secretin</keyword>
	<keyword>Secretin-enhanced MRCP</keyword>
	<keyword>Endoscopic pancreatic function test</keyword>
	<keyword>Pancreatic exocrine insufficiency</keyword>
</DOC>